← Leaderboards
Weidong Xu
Endeavor Health Clinical Operations
$1,961,125
Attributed
$1,961,125
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $416.3K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,961,125 · 1
By mechanism
R01$1,961,125 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Breast Cancer Treatment”
- Greg Yothers · University Of Chicago$35,003,821
- Olwen Hahn · Brigham And Women'S Hospital$32,185,622
- Jessica Scott · Sloan-Kettering Inst Can Research$10,553,540
- Kathleen Nicol · Research Inst Nationwide Children'S Hosp$7,152,405
- Philip Chow · University Of Virginia$5,923,840
- Andrew Chapman · Thomas Jefferson University$5,748,480
Research focus
Breast Cancer TreatmentClinical TrialsAbraxaneBreast Cancer PatientCell DeathCellsAntibodiesAdenovirusesAntibody Titer MeasurementAnti-Pd-L1Anti-Ctla4Amino AcidsAnti-Ctla-4 TherapyAnti-Tumor Immune ResponseAntitumor ResponseAttenuatedAnti-Pd1 AntibodiesBindingBiological MarkersAnti-Pd-1/Pd-L1BoneBreast Cancer CellBreast Cancer ModelCombination Immunotherapy
Grant awards (5)
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer$416,290
R01 · FY2025 · CA · contact PI
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer$396,958
R01 · FY2024 · CA · contact PI
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer$378,315
R01 · FY2023 · CA · contact PI
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer$374,436
R01 · FY2022 · CA · contact PI
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer$395,126
R01 · FY2021 · CA · contact PI